Infants, Jobs And CT99021

pT2-4, P=0.9565). The PD-1 ?606 were 80 AA (23.0%), 184 GA (52.9%), 84 GG (24.1%) at stage I; 28 AA (29.2%), 44 GA (45.8%), 24 GG (25%) at stage II; and 38 AA (27.3%), 65 GA (46.8%), 36 GG (25.9%) at stage III�CIV. The ratio of the GG phenotype was not significantly Selleckchem PLX4032 different between stage I vs.stages II�CIV (P=0.7018) (Table I). Table I Clinicopathological data of 583 lung cancer patients. The overall survival time of 583 lung cancer patients from Nagoya City University, with a follow-up until August 31, 2013, was studied in reference to the PD-1 gene ?606 SNP statuses. The survival time of the patients with the ?606 GG phenotype of PD-1 was significantly lower (n=147; 50 succumbed; mean survival, 60.6 months) compared to the patients with ?606 GA or ?606 AA (n=436; 110 succumbed; mean survival, 84.6 months) (log-rank test, P=0.0183) (Fig. 1). The survival rate of the SCC patients with the ?606 GG phenotype of PD-1 was also significantly lower (n=42; 18 succumbed; mean survival, 43.5 months) compared to the patients with ?606 GA or ?606 AA (n=124; 33 succumbed; mean survival, 84.3 months) (log-rank test, P=0.0090) (Fig. 2). The survival time of the stage I SCC patients with the ?606 GG phenotype this website of PD-1 was significantly worse (n=19; 8 succumbed; mean survival, 47 months) compared to the patients with ?606 GA or ?606 AA (n=66; 12 succumbed; mean survival, 95.2 months; P=0.0091). However, the survival time of the stage II�CIV SCC patients with the ?606 GG and GA or AA was not significantly different (P=0.2840). The survival time of the adeno patients with the ?606 GG phenotype of PD-1 (n=93; 28 succumbed; mean survival, 65.1 months) and with the patients PDGFRB with ?606 GA or ?606 AA (n=273; 68 succumbed; mean survival, 79.2 months) was not significantly different (P=0.2718). Univariate analysis demonstrated that pathological stage (I vs. II�CIV, P